EU/Europe

This systematic review indicates that hepatitis C treatment uptake is relatively low among drug users in several European countries, and also points to considerable knowledge gaps regarding treatment uptake levels in this...

The systematic collection of data on ED presentation of toxicity related to NPS and classical drugs in Europe is scarce and the collection of data is highly variable between different countries. Euro-DEN...

An overview of regulatory approaches to new psychoactive substances (NPS) in the European Union.

May 2014 saw the launch of the European drug report (EDR), the European Monitoring Centre for Drugs and Drug Addiction’s (EMCDDAs) annual review of the European drug market, incorporating trend analysis, topic...

This editorial gives a summary of the EMCCDA 'Insights' publication examining the comorbidity, or dual diagnosis, of mental health issues alongside drug use in the European Union

This scoping study was based on a targeted multi-source data collection exercise focusing on the provision of health and drug interventions associated with NPS use and harms, in selected intervention settings across...

This article examines the evidence for quality assurance systems for drugs-related interventions in Europe, based on information gathered by the EMCDDA.

In June 2014 the Athens High Level Meeting discussed recent policy developments, persisting and emerging challenges related to the prevention and management of viral hepatitis and the need for a de minimis...

This article synthesizes data on European drug markets collected and analysed by the EMCDDA in 2016.

Psychosis can be associated with acute recreational drug and novel psychoactive substance (NPS) toxicity. However, there is limited data available on how common this is and which drugs are most frequently implicated...